CP
CHO Pharma at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
CHO Pharma takes part in 1 session at World Vaccine Congress Europe 2026 in Amsterdam, and exhibits. Its program centres on its K1/K2 glycoconjugate vaccine against hypervirulent, meaning especially aggressive, Klebsiella pneumoniae bacteria. It shares early safety results, and early data on whether the immune responses the vaccine triggers actually work, from its first trial in people.
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
CP CHO Pharma | |
Develops glycoconjugate vaccines, including a K1/K2 vaccine against hypervirulent Klebsiella pneumoniae in first-in-human trials. | Booth Exhibiting (no floor booth listed) |
Instantly find 20 buyers from CHO Pharma
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction